医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Novacyt and Leica Biosystems Sign Major Distribution Deal for NOVAprep® in Greater China

2015年03月04日 PM03:13
このエントリーをはてなブックマークに追加


 

PARIS & CAMBRIDGE, England

Novacyt (ALTERNEXT:ALNOV), an international specialist in cancer and infectious disease diagnostics, and Leica Biosystems, a leading supplier to the pathology market, have today signed an agreement where Leica Biosystems will have exclusive distribution of Novacyt’s NOVAPrep® cytology platform in Greater China markets.

China is the fastest growing market for cervical cancer screening today. By 2020 it is expected to be significantly larger than the US market and will then be the number one market for liquid based cytology screening for the disease. There are estimated to be 60 million cervical cancer screening tests performed annually in China today and by 2020 this could grow to 150 million cervical cancer screening tests per year.

The distribution partnership combines the commercial strength of Leica Biosystems in the Chinese Pathology market, with Novacyt’s innovative next generation NOVAPrep® cytology platform which has recently received CFDA approval for the Chinese market. The agreement has an initial term of five years and covers Greater China including mainland China, Hong Kong, Macau and Taiwan.

Francis Kee, Vice President & General Manager Greater China, Leica Biosystems, commented, “Novacyt has developed an innovative and proprietary next generation liquid based cytology system. This will add to the broad offering of pathology products Leica offers pathologists and histology professionals today. The fast growing Chinese healthcare market is of key importance to Leica and we look forward to being able to expand our customer offering with the innovative NOVAPrep® technology”

Graham Mullis, Group CEO of Novacyt, commented, “We are delighted to announce this distribution partnership with Leica Biosystems, a leading supplier to the pathology market. We believe Leica Biosystems is an excellent partner for Novacyt to penetrate the fastest growing cytology market in the world. This deal is a significant endorsement of the quality and performance of our NOVAPrep® technology. It marks the beginning of our global expansion strategy.”

NOVAPrep® is expected to be launched in China during the second half of 2015. This deal is transformational to Novacyt’s NOVAPrep® sales.

CONTACT

International Investor & Media
Tony Stephenson, +44
(0)7899 796655
Exitus Communications
tony@exituscommunications.co.uk

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明
  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結